UNIVAX WINRHO SD "LOWER COST PROFILE" WILL BE PROMOTIONAL FOCUS
Executive Summary
UNIVAX WINRHO SD "LOWER COST PROFILE" WILL BE PROMOTIONAL FOCUS in detailing the polyclonal antibody product to prescribers of intravenous immunoglobulin for idiopathic thrombocytopenic purpura, President and CEO Thomas Stagnaro told the Robertson, Stephens annual medical conference in New York City Nov. 30. Stagnaro said the company's initial marketing efforts will "attack" the ITP market by "target[ing] all of our efforts on conversion of current IGIV prescribers."